migraine%20headache
MIGRAINE HEADACHE
Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia &/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines &/or vision loss, sensory symptoms of pins & needles &/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms &/or unilateral sensory symptoms or at least 1 aura symptoms develop gradually over ≥5 minutes &/or different aura symptoms that occur in succession over ≥5 minutes.

Classification

Diagnostic Criteria

Migraine Headache without Aura

  • At least 5 attacks with any 2 of the following headache characteristics and should last from 4-72 hours without signs of secondary headache:
    • Unilateral
    • Throbbing or pulsating in nature
    • Pain is considered moderate to severe
    • Usual physical activity (eg walking or climbing stairs) aggravates pain
  • Plus any one of the following symptoms:
    • Nausea and vomiting
    • Photophobia and/or phonophobia

Migraine Headache with Aura

  • Headache with accompanying or preceding transient focal neurological symptoms
  • At least 2 attacks with ≥1 of the following fully reversible symptoms but without motor weakness:
    •  Visual symptoms including positive features (flickering lights, spots or lines) and/or negative features (loss of vision)
    • Sensory symptoms including positive features (pins and needles) and/or negative features (numbness)
    • Dysphasic speech disturbance
    • Motor
    • Brainstem
    • Retinal
  • At least 2 of the following:
    • At least 1 aura symptom develops gradually over ≥5 minutes and/or different aura symptoms that occur in succession
    • Every aura symptom lasts 5-60 minutes
    • At least 1 unilateral aura symptom
    • Headache occur with the aura or 60 minutes after the aura

Diagnosis

Status Migrainosus

  • Usually severe and debilitating migraine headache that requires aggressive treatment
  • Often caused by medication (eg analgesic) overuse
  • Treatment may start with intravenous fluids and electrolyte replacement if indicated
  • Some patients may need hospitalization for rehydration, control of vomiting by giving antiemetics and abortive therapy
  • Abortive therapy includes parenteral triptan without ergot and/or Dihydroergotamine 8-12 hours after the lastdosage of triptan
  • Ketorolac intramuscular/intravenous or sodium valproate can be given if Dihydroergotamine or triptan is contraindicated or ineffective

Evaluation

  • Therapy decision is made based on severity of headache

Severity Categories

Moderate

  • Patient is not completely incapacitated but daily activities are greatly hindered by headache

Severe

  • Patient’s daily activities are not performed or they are greatly altered because of headache

Status migrainosus

  • Severe headache that lasts >72 hours

Evaluation to determine if patient should receive migraine prophylactic treatment

  • When indicated, prophylactic treatment should be used in addition to acute therapy

Indication for prophylactic therapy may be based on:

  • Frequency of attacks is ≥2 per month
  • Patient feels that migraines are significantly interfering with their normal daily activities even with acute treatment lasting for >3 days per month
  • Failure and contraindication of acute therapies
  • Overuse of acute therapy, ie >2x per week
  • Adverse effects from acute therapies
  • Patient preference
  • Cost of acute therapy
  • Presence of neurologic damage from uncommon migraine types 

Assessment

Initial assessment should include but is not limited to:

  • Detailed history
    • Headache characteristics (nature of pain, severity, location, frequency, duration)
    • Functional impairment
    • Accompanying symptoms
    • Past medical history
    • Family history of migraines
    • Social history
    • Medical history
  • Thorough physical and neurological examination
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, Yesterday
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.